Using ultrasound and drugs to improve treatment for liver cancer
A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment
This study is looking at a new way to help people with liver cancer by using sound waves to improve how well chemotherapy works, making it easier for the medicine to reach the tumor and hopefully leading to better results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11094055 on NIH RePORTER |
What this research studies
This research aims to enhance the treatment of hepatocellular carcinoma (HCC) by combining ultrasound cavitation with mechanotherapeutic drugs. The approach focuses on modifying the tumor microenvironment to improve the effectiveness of existing chemotherapy treatments. By using advanced imaging techniques, the study will monitor how these combined therapies affect tumor characteristics, potentially leading to better drug absorption and improved patient outcomes. The goal is to make this innovative treatment widely available for future clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who are not suitable for surgical removal or ablation.
Not a fit: Patients with early-stage liver cancer who can undergo surgical treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of chemotherapy for liver cancer patients.
How similar studies have performed: Other research has shown promise in using ultrasound and drug combinations to enhance cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Averkiou, Michalakis — University of Washington
- Study coordinator: Averkiou, Michalakis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.